COMMUNIQUÉS West-GlobeNewswire

Grant of Restricted Stock Units and Warrants to Employees in Genmab
29/01/2026
Company Announcement COPENHAGEN, Denmark; January 29, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 32,806 restricted stock units and 34,307 warrants to employees of the [...]
QTX-2101 Awarded FDA Fast Track Designation for the Treatment of Acute Promyelocytic Leukemia
29/01/2026
CHICAGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Quetzal Therapeutics, a biopharmaceutical company focused on developing treatments for rare diseases, announced that the U.S. Food and Drug Administration (FDA) has granted [...]
PCI Biotech initiates a process to evaluate the opportunity for a structured wind-up process
29/01/2026
Oslo (Norway), 29 January 2026 – PCI Biotech (OSE: PCIB) refers to its latest announcement of 8 January 2026 regarding the discontinuation of all R&D operations and the continued exploration of strategic [...]
Longeveron® Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)
29/01/2026
The patent relates to potency assay methods for assessing human mesenchymal stem cells (MSCs) derived from bone marrow, adipose tissue, peripheral blood, a lung, a heart, amniotic fluid, inner organs, an amniotic [...]
Panakeia publishes landmark clinical validation showing AI can deliver rapid molecular profiling for colorectal cancer
29/01/2026
Panakeia publishes landmark clinical validation showing AI can deliver rapid molecular profiling for colorectal cancer Largest real-world, blinded, multi-site validation of AI molecular profiling from routine diagnostic [...]
Alira Health Opens the Registration for the Third Edition of the Global Payer Forum
29/01/2026
An Annual Global Event Examining the Key Trends Reshaping Access to Healthcare Innovation FRAMINGHAM, Mass., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Alira Health today opens the registration for the third edition of its [...]
Vystar Enters Final Testing of Breakthrough Dialysis Water Filtration Technology
29/01/2026
FEC Expands Reach Into New Vertical Markets Vystar plans to apply Fluid Energy Conversion (FEC) technology to increase pathogen killing efficiency, reduce size and cost of Vystar’s RxAir air purifiers. FEC technology [...]
Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead
29/01/2026
- Expecting very active 2026 from a clinical perspective, including significant patient accrual completions and subsequent data readouts from ReSTART pivotal skin cancer trial as well as trials in cancers of internal [...]
JenaValve Appoints John Molyneux to Vice President of Operations
29/01/2026
IRVINE, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced the appointment of John Molyneux to Vice [...]
ALK receives positive recommendation for EURneffy® 1 mg: A needle-free anaphylaxis treatment for children
29/01/2026
Inside Information ALK (ALKB:DC / OMX: ALK B) today announced that the Committee for Medicinal Products for Human Use (‘CHMP’) of the European Medicines Agency has adopted a positive opinion recommending the granting of [...]
Gameto Licenses Foundational Meiosis IP from Harvard to Advance Human Ovary-in-a-Dish Platform
29/01/2026
Newly licensed intellectual property enables genetic induction of early meiosis, further strengthening Gameto’s best-in-class platform for modeling human ovarian development and disease AUSTIN, Texas, Jan. 29, 2026 ( [...]
Father–Daughter Duo Brings Patented Recovery Sleeves to Target.com
29/01/2026
Tampa, FL, Jan. 29, 2026 (GLOBE NEWSWIRE) -- While many Americans remain focused on their new year’s resolutions, there are also many living in pain, recovering from an injury or surgery and looking desperately for a [...]
Elevar Therapeutics Names Dong-Gun Kim CEO as It Focuses on Post-NDA Commercialization Strategy
29/01/2026
Former CEO Dr. Bryan Kim will retain current role as CEO of Verismo Therapeutics FORT LEE, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Group and a fully [...]
Governor Desantis Appoints Dr. Chadwick Marshall to Serve on Florida Board of Dentistry
29/01/2026
IRVING, Texas and FORT WALTON BEACH, Fla., Jan. 29, 2026 (GLOBE NEWSWIRE) -- U.S. Oral Surgery Management (USOSM) congratulates its surgeon partner Chadwick J. Marshall , DMD, MD, who was recently appointed by Governor [...]
Fractyl Health Announces Compelling 6-Month Randomized REMAIN-1 Midpoint Data Showing Durable Weight Maintenance with Revita® After GLP-1 Discontinuation
29/01/2026
Revita-treated patients experienced sustained weight maintenance, improved cardiometabolic profile, and reduced food cravings at 6 months compared with sham, with continued excellent safety and tolerability Patients [...]
Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference
29/01/2026
SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health [...]
Terrapin Beer Co. Turns Up the Volume with a New Brand Identity Rooted in Music, Art and Craft Beer Culture
29/01/2026
A modern visual evolution designed to amplify artistic storytelling across the brand portfolio ATHENS, Ga., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Terrapin Beer Co. (Terrapin), a craft beer brand by Tilray Brands, Inc. ( [...]
Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader
29/01/2026
Data from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027 Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial is expected to be reported by mid-2027 WATERTOWN, Mass., Jan. [...]
OMEICOS Therapeutics Announces Positive Phase 2 Study Outcome Demonstrating OMT-28’s Potential in Primary Mitochondrial Diseases (PMD)
29/01/2026
Trial Results Support Transition into Late-Stage Development with Program Expected to be Phase 2b/3-ready in H2 2026 BERLIN, GERMANY, January 29, 2026 – OMEICOS, a clinical-stage biopharmaceutical company developing [...]

Pages